AMS (AMS) Q1 2026: 15.9% Revenue Growth Reflects Direct Patient Care Expansion and Margin Improvement
American Shared Hospital Services demonstrated robust growth in its direct patient care segment, driving a 15.9% revenue increase alongside notable margin expansion. Operational improvements and higher treatment volumes underpin improving profitability, setting a foundation for continued growth as new centers ramp up utilization. The company’s strategic shift from equipment leasing to patient-centric services is gaining traction, supported by expanding international and U.S. footprints.
Summary
- Patient-Centric Growth Momentum: Expansion of direct patient care services in Rhode Island and Mexico is accelerating revenue and procedure volumes.
- Operational Efficiency Gains: Improved gross margins and reduced operating losses highlight better cost management amid growing service volumes.
- Growth Pipeline Visibility: New centers under development and international expansion signal sustained long-term growth potential.
Business Overview
American Shared Hospital Services (AMS) operates as a provider of advanced radiation therapy cancer treatment services and medical equipment leasing. The company generates revenue primarily through two segments: direct patient care services, which involves delivering radiation therapy treatments at owned or joint venture centers, and medical equipment leasing, which includes leasing stereotactic radiosurgery and proton beam equipment to health systems. AMS is actively transitioning its business model toward direct patient care services to capture higher growth and margin opportunities.
Performance Analysis
AMS reported total revenue of $7.1 million for the first quarter of 2026, reflecting a 15.9% increase year-over-year driven predominantly by a 30.2% rise in direct patient care services revenue to $4.1 million. This growth was fueled by increased procedure volumes at the Rhode Island radiation therapy centers and the Puebla, Mexico facility, with Gamma Knife procedures up 10.1% and proton beam radiation therapy (PBRT) treatments rising 20.7%. Leasing revenue remained steady at $3.0 million despite the expiration of a Gamma Knife customer contract in April 2025, indicating resilience in the equipment leasing segment amid ongoing strategic shifts.
Gross margin expanded significantly by 36.7% to $1.3 million, or 18.2% of revenue, reflecting improved utilization and operational efficiencies in the direct patient services segment. Operating loss narrowed to $0.9 million from $1.3 million a year ago, partly due to margin improvements and despite increased operating expenses related to staffing and facility costs at ramping centers. Adjusted EBITDA increased 18.4% to $1.1 million, underscoring enhanced underlying profitability as the company scales its patient care operations.
- Volume-Driven Revenue Expansion: Growth in direct patient care procedures, especially at Rhode Island and Puebla centers, is the primary driver of revenue gains.
- Margin Improvement Despite Cost Increases: Higher utilization offsets increased staffing and maintenance expenses, resulting in expanded gross margins.
- Stable Leasing Revenue Amid Contract Expirations: Equipment leasing revenue held steady, demonstrating resilience despite normal contract attrition.
Overall, AMS’s financial results reflect a successful execution of its strategic pivot toward direct patient care, with operational scale and utilization gains driving improved profitability metrics.
Executive Commentary
"We are encouraged by our performance in the first quarter of 2026, which reflects continued momentum in our direct patient care services segment and improved utilization across our treatment centers. Revenue growth of approximately 16% year-over-year was driven by strong contributions from our Rhode Island and Puebla radiation therapy centers, as well as growth in proton therapy volumes which is continuing into the second quarter."
Craig Tagawa, Interim Chief Executive Officer
"Our first quarter performance highlights the strength of our operating model, as higher treatment volumes translated into improved margins and a significant reduction in operating loss. Additionally, I am pleased to report that we are continuing to see volumes trending higher into the second quarter. As utilization continues to ramp up across our network, we expect to drive further margin expansion and increased profitability."
Scott Frech, Chief Financial Officer
Strategic Positioning
1. Shift Toward Direct Patient Care Services
AMS is accelerating its transition from an equipment leasing model to a patient-centric service model, which now represents the majority of revenue. This shift aligns with higher growth potential and improved margins, as evidenced by the 30.2% increase in direct patient care revenue. The company’s investments in staffing, facility upgrades, and new center openings support this strategic pivot.
2. Geographic Expansion and New Centers
The company’s footprint is expanding notably with the ramp-up of three Rhode Island radiation therapy centers and the Puebla, Mexico facility. Additionally, AMS is progressing on two significant projects: a fourth radiation therapy center in Bristol, Rhode Island, and the state’s first proton beam radiation therapy center. Internationally, the upcoming gamma knife center in Guadalajara, Mexico, poised to open in Q2 2026, offers a substantial growth opportunity in an underserved market.
3. Operational Efficiency and Margin Expansion
Despite increased operating costs associated with ramping centers, AMS achieved a 36.7% gross margin increase year-over-year. Improved utilization of treatment equipment and scale benefits are driving better cost absorption, enhancing profitability metrics such as adjusted EBITDA and operating loss reduction.
4. Balanced Capital Structure and Liquidity Management
The company maintains a solid balance sheet with $5.2 million in cash and a manageable debt position. Management is actively engaging with lenders to optimize capital structure and support growth investments while controlling interest expenses, which declined compared to the prior year.
5. Leveraging Clinical Partnerships and Market Position
AMS’s relationships with health system partners, including Care New England and Prospect Charter Care in Rhode Island, are critical to driving patient volume growth and market penetration. The company’s focus on physician engagement and community awareness aims to sustain and accelerate utilization gains across its network.
Key Considerations
The first quarter reflects AMS’s strategic progress but also highlights operational challenges inherent in scaling patient care services. Investors should weigh the following:
- Patient Volume Growth as a Profitability Driver: Continued ramp-up at Rhode Island and Mexican centers is essential to sustaining margin expansion.
- Cost Structure Evolution: Increased staffing and maintenance costs underscore the need for operational discipline as the company grows.
- Contract Expirations and Leasing Segment Stability: The equipment leasing business faces attrition risks but remains a steady revenue contributor.
- Capital Allocation for Growth Projects: Investments in new centers and equipment require balanced capital management to avoid liquidity constraints.
- Investor Relations and Market Visibility: Management acknowledges the need for enhanced investor outreach to better communicate progress and value creation.
Risks
AMS faces risks including potential delays in new center openings, reimbursement rate fluctuations, and operational challenges in ramping complex treatment facilities. The company’s reliance on physician referrals and health system partnerships introduces execution risk, while the competitive landscape for advanced radiation therapy services may pressure volumes and pricing. Additionally, maintaining financial flexibility amid capital-intensive growth is a critical risk factor.
Forward Outlook
For the second quarter of 2026, AMS expects continued volume growth, particularly in direct patient care services, supporting further margin expansion and improved operating results. Management anticipates ramp-up momentum at Rhode Island and Puebla centers will persist, with the Guadalajara gamma knife center commencing operations in Q2. Full-year guidance was not explicitly updated but reflects confidence in ongoing growth and profitability improvements.
- Volumes trending higher into Q2 support revenue and margin gains.
- New center openings and international expansion to contribute incremental growth.
Takeaways
AMS’s Q1 2026 results underscore a successful strategic transition toward direct patient care services, driving meaningful revenue growth and margin improvement. Operational execution in ramping treatment centers, combined with geographic expansion, forms the backbone of its growth trajectory. Investor skepticism due to limited market visibility remains a challenge but management is increasingly focused on outreach to bridge this gap.
- Patient Care Growth Drives Financial Improvement: The 30.2% increase in direct patient services revenue is the primary engine for margin expansion and reduced operating losses.
- Strategic Expansion Enhances Market Position: New centers in Rhode Island and Mexico, plus planned projects, position AMS for sustained growth in underserved markets.
- Investor Outreach as a Catalyst: Enhanced communication and market engagement are critical to aligning valuation with operational progress.
Conclusion
American Shared Hospital Services is executing a clear strategic pivot toward patient-centric cancer treatment services, which is driving top-line growth and improving profitability. The company’s expanding footprint and operational efficiencies provide a solid foundation for long-term value creation, though investor recognition and capital management remain important focal points going forward.
Industry Read-Through
AMS’s results highlight broader industry trends favoring integrated cancer care delivery models over traditional equipment leasing. The shift toward direct patient services reflects growing demand for localized, advanced radiation therapy treatments. The challenges of ramping new centers and managing reimbursement pressures are common across the sector, underscoring the importance of operational excellence and strategic partnerships. Additionally, international expansion into underserved markets like Mexico illustrates growth opportunities for radiation therapy providers willing to invest in emerging regions.